MSA with Global Pharmaceutical Company
CelLBxHealth plc has announced a significant Master Services Agreement with AstraZeneca, positioning CelLBxHealth as a qualified service provider to support drug discovery and development. This agreement will leverage CelLBxHealth's CTC-powered analytics, utilizing the Parsortix® platform to analyze clinical trial samples. The company anticipates strong and productive outcomes from this collaboration, which allows AstraZeneca to access CelLBxHealth's capabilities across its development pipeline.
Select text to share a quote on X · sign in to keep highlights & notes in your CLBX notes
Guildford, UK and Plymouth Meeting, U.S. - 29 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that it has entered into a Master Services Agreement with AstraZeneca.
The agreement establishes CelLBxHealth as a qualified service provider to AstraZeneca, enabling the Company to support drug discovery and development through CTC powered analytics of clinical trial samples using the Parsortix® platform.
Peter Collins, Chief Executive Officer of CelLBxHealth, commented: "We are delighted to enter into this Master Services Agreement which enables AstraZeneca to access our capabilities across their development pipeline. We look forward to delivering strong and productive outcomes through this framework."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.